NSCLC, which represents 75–80% of the cases and includes adenocarcinoma, squamous cell carcinoma, and large-cell carcinoma, originates from activating mutations in EGFR, ALK, ROS 1 proto-oncogene receptor tyrosine kinase, and BRAF genes. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.